Skip to main content
NVDA+0.56%AAPL+0.02%GOOGL-0.61%MSFT+0.28%AMZN+0.36%TSM+0.96%SPCX+5.15%META+0.38%AVGO+0.07%TSLA+0.31%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.68%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%ORCL+2.00%BAC-2.72%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%3988.HK+0.34%GE+1.91%1816.HK-0.69%MS-1.83%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%USDJPY+1.74%NZDUSD-1.63%AUDUSD-1.17%USDCHF+1.15%EURUSD-1.13%GBPUSD-1.07%USDTHB+1.06%CADJPY+0.92%USDCAD+0.84%NZDCAD-0.82%CHFJPY+0.71%GBPJPY+0.63%EURJPY+0.57%GBPNZD+0.57%AUDJPY+0.56%EURNZD+0.51%NZDCHF-0.51%AUDNZD+0.47%GBPTRY+0.41%EURCAD-0.34%AUDCAD-0.34%USDTRY+0.33%GBPHKD+0.32%CADCHF+0.30%GBPMXN-0.28%GBPCAD-0.25%USDILS+0.16%NZDMXN+0.10%NZDJPY+0.10%GBPAUD+0.09%NZDSGD+0.08%USDCNH+0.07%EURAUD+0.05%AUDSGD-0.04%GBPCHF+0.04%USDCOP-0.04%EURGBP-0.04%USDZAR+0.03%GBPSGD-0.03%AUDCHF-0.03%USDSGD-0.03%USDHKD+0.02%EURCHF+0.02%USDMXN+0.01%SGDJPY+0.01%EURSGD0.00%CHFSGD0.00%EURSEK0.00%GBPZAR0.00%PLNJPY0.00%USDSEK0.00%EURNOK0.00%EURDKK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%NOKJPY0.00%USDPLN0.00%EURCZK0.00%CHFNOK0.00%USDNOK0.00%USDDKK0.00%EURPLN0.00%XPTUSD+0.64%USOIL-0.30%XNGUSD+0.27%XAUUSD+0.25%GAUUSD+0.25%XAGUSD+0.13%GAGUSD+0.13%HG1+0.09%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.13%ETHUSD-0.09%USDTUSD+0.01%XRPUSD+0.21%SOLUSD+0.73%TRXUSDT+0.79%ZECUSDT+17.74%DOGEUSD+0.14%XMRUSDT-3.45%LINKUSD+0.04%XLMUSD+1.93%BCHUSDT+0.64%UNIUSD+0.54%LTCUSD-0.60%TONUSD+29.54%HBARUSDT-2.00%SUIUSD+2.26%TAOUSDT+0.46%AAVEUSD-2.46%DOTUSDT+6.14%ICPUSDT+1.52%ONDOUSDT+2.86%WLDUSDT+1.27%ARBUSDT+7.53%ATOMUSDT-1.81%JUPUSDT-1.65%INJUSDT-1.28%STXUSDT+2.00%FETUSDT+2.34%PYTHUSDT-1.53%TIAUSDT+2.39%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.80%OPUSDT-0.14%WIFUSDT+1.40%POLUSDT+1.09%IOTAUSDT-0.63%AXSUSDT+0.14%FARTCOINUSDT-1.34%EOSUSDT-0.58%DYDXUSDT-0.20%ORDIUSDT+2.87%GALAUSDT-2.76%NOTUSDT+1.37%RONINUSDT-2.40%NVDA+0.56%AAPL+0.02%GOOGL-0.61%MSFT+0.28%AMZN+0.36%TSM+0.96%SPCX+5.15%META+0.38%AVGO+0.07%TSLA+0.31%SKHY+0.02%BRK-B+0.59%LLY+0.18%MU+0.68%JPM-1.01%WMT-0.55%AMD+1.65%V-1.25%XOM-3.54%JNJ+0.03%ASMLa+1.26%INTC+4.03%0700.HK-1.23%MA-0.96%ABBV-0.17%1398.HK+0.67%CSCO-2.12%CVX-2.86%ORCL+2.00%BAC-2.72%COST-0.84%KO-0.95%DELL+3.64%CAT-0.10%0005.HK+0.81%PG+0.24%HSBA.L+0.27%UNH-0.18%LRCX-0.61%AP2d+0.95%AMAT-1.37%3988.HK+0.34%GE+1.91%1816.HK-0.69%MS-1.83%NFLX-1.91%0857.HK-1.90%HD-0.99%PM-1.24%0939.HK+0.31%USDJPY+1.74%NZDUSD-1.63%AUDUSD-1.17%USDCHF+1.15%EURUSD-1.13%GBPUSD-1.07%USDTHB+1.06%CADJPY+0.92%USDCAD+0.84%NZDCAD-0.82%CHFJPY+0.71%GBPJPY+0.63%EURJPY+0.57%GBPNZD+0.57%AUDJPY+0.56%EURNZD+0.51%NZDCHF-0.51%AUDNZD+0.47%GBPTRY+0.41%EURCAD-0.34%AUDCAD-0.34%USDTRY+0.33%GBPHKD+0.32%CADCHF+0.30%GBPMXN-0.28%GBPCAD-0.25%USDILS+0.16%NZDMXN+0.10%NZDJPY+0.10%GBPAUD+0.09%NZDSGD+0.08%USDCNH+0.07%EURAUD+0.05%AUDSGD-0.04%GBPCHF+0.04%USDCOP-0.04%EURGBP-0.04%USDZAR+0.03%GBPSGD-0.03%AUDCHF-0.03%USDSGD-0.03%USDHKD+0.02%EURCHF+0.02%USDMXN+0.01%SGDJPY+0.01%EURSGD0.00%CHFSGD0.00%EURSEK0.00%GBPZAR0.00%PLNJPY0.00%USDSEK0.00%EURNOK0.00%EURDKK0.00%EURHKD0.00%AUDNOK0.00%EURCNH0.00%EURZAR0.00%AUDDKK0.00%CHFSEK0.00%NOKJPY0.00%USDPLN0.00%EURCZK0.00%CHFNOK0.00%USDNOK0.00%USDDKK0.00%EURPLN0.00%XPTUSD+0.64%USOIL-0.30%XNGUSD+0.27%XAUUSD+0.25%GAUUSD+0.25%XAGUSD+0.13%GAGUSD+0.13%HG1+0.09%C10.00%SUGAR0.00%COTTON0.00%COFFEE0.00%BTCUSD+0.13%ETHUSD-0.09%USDTUSD+0.01%XRPUSD+0.21%SOLUSD+0.73%TRXUSDT+0.79%ZECUSDT+17.74%DOGEUSD+0.14%XMRUSDT-3.45%LINKUSD+0.04%XLMUSD+1.93%BCHUSDT+0.64%UNIUSD+0.54%LTCUSD-0.60%TONUSD+29.54%HBARUSDT-2.00%SUIUSD+2.26%TAOUSDT+0.46%AAVEUSD-2.46%DOTUSDT+6.14%ICPUSDT+1.52%ONDOUSDT+2.86%WLDUSDT+1.27%ARBUSDT+7.53%ATOMUSDT-1.81%JUPUSDT-1.65%INJUSDT-1.28%STXUSDT+2.00%FETUSDT+2.34%PYTHUSDT-1.53%TIAUSDT+2.39%SEIUSDT+1.07%IMXUSDT-1.25%GRTUSDT+1.80%OPUSDT-0.14%WIFUSDT+1.40%POLUSDT+1.09%IOTAUSDT-0.63%AXSUSDT+0.14%FARTCOINUSDT-1.34%EOSUSDT-0.58%DYDXUSDT-0.20%ORDIUSDT+2.87%GALAUSDT-2.76%NOTUSDT+1.37%RONINUSDT-2.40%
EP

EyePoint Pharmaceuticals, Inc. (EYPT)

NASDAQ • Healthcare

$3.45
-$0.2 (-5.7%)
Market closed

Last close at September 16, 2026 at 20:00 UTC

Open$3.66
Day Range$3.42 - $3.74
Avg. Volume (3M)4.8M
Market Cap$289.2M
52 Week Range
$3.42$19.11
Next EarningsIn 49 daysNov 4, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$507K100%
Gross Profitminus cost of goods$507K100%

Fundamentals & Financials

Revenue (TTM)
$2.7M
Net Income (TTM)
-$306.6M
EPS (TTM)
-$3.74
ROA (TTM)
-134.38%
Current Ratio
4.5

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-3.8%Q1 2026-$0.81
-25.3%Q2 2026-$0.99
-7.9%Q3 2026-$1.09
Next

Nov 4

in 49 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -7.9%

EyePoint Pharmaceuticals trailed consensus on EPS but topped it on revenue in the second fiscal quarter of 2026, reported August 5, 2026, as revenue fell 90.5% to roughly $0.5 million from about $5.3 million a year ago. Revenue of $507,000.00 topped the $451,214.00 estimate, +12.4%, while EPS of -$1.09 trailed the -$1.01 estimate by -$0.08 (down from -$0.85 a year ago). With gross profit matching revenue at roughly $0.5 million, the quarter still posted an operating loss of about $97.4 million, and net income came in at a loss of roughly $94.5 million, improving 59.0% from a loss of about $59.4 million a year earlier. The company’s marketed ophthalmic portfolio includes ILUVIEN, YUTIQ, and DEXYCU. For the next period, consensus calls for EPS of -$0.91 on revenue of $232,154.00.

View full earnings history

About EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc. develops and markets ophthalmic therapies for retinal and other eye disorders as a biotechnology company in healthcare. Trading on the NASDAQ Global Market as EYPT, it generates $31.4 million in FY2025 revenue from commercial eye-disease products and a pipeline aimed at chronic and sight-threatening conditions.

Name
EyePoint Pharmaceuticals, Inc.
CEO
Jay S. Duker
Website
www.eyepoint.bio
Industry
Healthcare
Year Founded
1987
Employees
214

Today's Snapshot

AI-generated

EYPT closed 5.7% below yesterday's close, while its sector was flat. Shares changed hands at about half as much again as its usual level.

Trading Volume

Above 10d avg 3.3M

4.9M

vs S&P 500 Today

Strong Underperformance

-5.16%

Updated: September 16, 2026 at 20:40 UTC

Technical Indicators

2 Buy1 Neutral5 Sell
EYPT shows a clear strong-sell profile with a high ADX signifying a solid downtrend and negative momentum measures reinforcing the decline while price remains far below its medium and long-term averages. Volatility is elevated with ATR implying very large percentage moves and OBV is materially negative, indicating persistent distribution. Short-term oscillators are deeply oversold, signaling extreme conditions but not negating the broader technical deterioration, and the pivot level sits above the current price. Technical takeaway: Strong Sell.
All signals
  • EMA (5 indicators)$4.26 - $12.06
    Sell
  • RSI (14)24.83
    Buy
  • Stochastic %K (14, 3, 3)5.30
    Buy
  • MACD Level (12, 26)-1.60
    Neutral

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$23.35-2.3%
NRIXNurix Therapeutics, Inc.
$25.15+1.3%
KODKodiak Sciences Inc.
$32.77-0.7%
SEPNSepterna Inc
$38.44-1.1%
BCAXBicara Therapeutics Inc. Common Stock
$22-3.0%
SVRASavara Inc.
$5.13-2.5%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.